US5681714A
(en)
*
|
1992-07-30 |
1997-10-28 |
Mount Sinai Hospital Corporation |
Nucleic acid encoding tek receptor tyrosine kinase
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6245530B1
(en)
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
US6818220B1
(en)
|
1994-11-14 |
2004-11-16 |
Licentia Ltd. |
Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
|
US6221839B1
(en)
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
ATE273384T1
(de)
*
|
1995-04-06 |
2004-08-15 |
Regeneron Pharma |
Tie-2 liganden, herstellungsverfahren und verwendung
|
AU755337B2
(en)
*
|
1995-04-06 |
2002-12-12 |
Regeneron Pharmaceuticals, Inc. |
New uses of tie-2 ligands
|
US7727761B2
(en)
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
ATE290077T1
(de)
|
1995-09-29 |
2005-03-15 |
Univ Siena |
Regulierte gene und ihre verwendungen
|
US7063965B2
(en)
*
|
1996-04-05 |
2006-06-20 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acid encoding TIE-2 ligand
|
DE19623850A1
(de)
*
|
1996-06-14 |
1997-12-18 |
Wacker Chemie Gmbh |
Homogenisierung von Dispersionen
|
US6846914B2
(en)
|
1996-06-19 |
2005-01-25 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligand-3
|
JP2000513932A
(ja)
|
1996-06-19 |
2000-10-24 |
リジェネロン ファーマシューティカルズ,インコーポレイテッド |
Tie―2レセプターリガンド(tieリガンド―3;tieリガンド―4)およびそれらの使用
|
US5851797A
(en)
*
|
1996-06-19 |
1998-12-22 |
Regeneron Pharmaceuticals, Inc. |
Tie ligand-3, methods of making and uses thereof
|
US6265564B1
(en)
*
|
1996-08-02 |
2001-07-24 |
Regeneron Pharmaceuticals, Inc. |
Expressed ligand-vascular intercellular signalling molecule
|
JP2001517075A
(ja)
|
1996-08-23 |
2001-10-02 |
ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ |
組換え血管内皮細胞増殖因子d(vegf―d)
|
US7125714B2
(en)
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
US5972338A
(en)
|
1997-09-19 |
1999-10-26 |
Genentech, Inc. |
Tie ligands homologues
|
US6350450B1
(en)
|
1997-09-19 |
2002-02-26 |
Genentech, Inc. |
TIE ligand homologue antibody
|
US6057435A
(en)
*
|
1997-09-19 |
2000-05-02 |
Genentech, Inc. |
Tie ligand homologues
|
US6030831A
(en)
*
|
1997-09-19 |
2000-02-29 |
Genetech, Inc. |
Tie ligand homologues
|
US6348350B1
(en)
|
1997-09-19 |
2002-02-19 |
Genentech, Inc. |
Ligand homologues
|
WO1999032639A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Regeneron Pharmaceuticals, Inc. |
Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis
|
WO1999032515A2
(en)
*
|
1997-12-19 |
1999-07-01 |
Zymogenetics, Inc. |
Angiopoietin homolog, dna encoding it, and method of making it
|
AU2493699A
(en)
*
|
1998-02-04 |
1999-08-23 |
Zymogenetics Inc. |
Angiopoietin homolog zapo3, dna encoding it, and method of making it
|
ATE466952T1
(de)
|
1998-03-02 |
2010-05-15 |
Massachusetts Inst Technology |
Poly-zinkfinger-proteine mit verbesserten linkern
|
JP2002516067A
(ja)
*
|
1998-03-02 |
2002-06-04 |
ミレニアム・フアーマシユーチカルズ・インコーポレーテツド |
新規fdrgタンパク質および核酸分子、ならびにそのための用途
|
US7488590B2
(en)
*
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6706687B1
(en)
|
1998-11-10 |
2004-03-16 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor D
|
CA2354846A1
(en)
|
1998-12-23 |
2000-06-29 |
Regeneron Pharmaceuticals, Inc. |
Method of enhancing the biological activity of ligands
|
JP2002537813A
(ja)
*
|
1999-03-02 |
2002-11-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アンギオポエチンに関連しているタンパク質および核酸
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
NZ514918A
(en)
|
1999-04-28 |
2003-11-28 |
Univ Texas |
Compositions and methods for cancer treatment by selectively inhibiting VEGF
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
EP1187918B9
(en)
*
|
1999-06-07 |
2009-08-19 |
Immunex Corporation |
Tek antagonists
|
DE60043367D1
(de)
|
1999-06-15 |
2009-12-31 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
US6689035B1
(en)
|
2000-04-11 |
2004-02-10 |
Gerber Scientific Products, Inc. |
Method and apparatus for designing and creating a package
|
CA2431308C
(en)
|
2000-12-07 |
2010-04-13 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7067317B2
(en)
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7205275B2
(en)
*
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003034990A2
(en)
|
2001-10-25 |
2003-05-01 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
JP4242590B2
(ja)
*
|
2002-01-11 |
2009-03-25 |
俊一 塩澤 |
慢性関節リウマチの疾患感受性遺伝子、及びその利用
|
US7427594B1
(en)
*
|
2002-02-26 |
2008-09-23 |
The Trustees Of The University Of Pennsylvania |
Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
|
US7081443B2
(en)
|
2002-05-21 |
2006-07-25 |
Korea Advanced Institutes Of Science And Technology (Kaist) |
Chimeric comp-ang1 molecule
|
US20040115640A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Isis Pharmaceuticals Inc. |
Modulation of angiopoietin-2 expression
|
CN1684706A
(zh)
|
2002-07-23 |
2005-10-19 |
路德维格癌症研究所 |
活化或抑制vegf-d和vegf-c的方法和组合物
|
WO2004045531A2
(en)
|
2002-11-14 |
2004-06-03 |
Cornell Research Foundation, Inc. |
Protection of cardiac myocardium
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
CN1323723C
(zh)
*
|
2003-12-26 |
2007-07-04 |
上海新世界基因技术开发有限公司 |
Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
|
US8298532B2
(en)
*
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
US20060024302A1
(en)
|
2004-03-05 |
2006-02-02 |
Ludwig Institute For Cancer Research |
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
KR101254815B1
(ko)
|
2004-07-20 |
2013-09-03 |
제넨테크, 인크. |
안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도
|
RU2394839C2
(ru)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Антитела против ангиопоэтина-2 и их применение
|
AP2007004095A0
(en)
*
|
2005-01-07 |
2007-08-31 |
Univ Emory |
Cxcr4 antagonists for the treatment of hiv infection
|
JP4657757B2
(ja)
*
|
2005-02-23 |
2011-03-23 |
株式会社膠原病研究所 |
肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
|
JP2006325528A
(ja)
*
|
2005-05-27 |
2006-12-07 |
Institute For Rheumatic Diseases Co Ltd |
糖尿病性網膜症の診断および予防
|
JP4657857B2
(ja)
*
|
2005-08-25 |
2011-03-23 |
株式会社膠原病研究所 |
メタボリックシンドロームの診断および予防
|
CN101370519B
(zh)
*
|
2005-12-15 |
2013-07-24 |
阿斯利康(瑞典)有限公司 |
治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトc−fms抗原結合性タンパク質
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
*
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
CN108864285A
(zh)
|
2008-01-03 |
2018-11-23 |
斯克里普斯研究院 |
通过模块识别结构域的抗体靶向
|
AU2009209251B8
(en)
|
2008-01-28 |
2015-03-26 |
Medimmune Limited |
Stabilized Angiopoietin-2 antibodies and uses thereof
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
US8268314B2
(en)
*
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
US8133979B2
(en)
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
KR101431318B1
(ko)
*
|
2009-04-02 |
2014-08-20 |
로슈 글리카트 아게 |
전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
US8980268B2
(en)
|
2009-07-29 |
2015-03-17 |
Regeneron Pharamceuticals, Inc. |
Methods for treating cancer by administering an anti-Ang-2 antibody
|
US20120189635A1
(en)
|
2009-07-29 |
2012-07-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
WO2011038139A1
(en)
|
2009-09-23 |
2011-03-31 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
AR080794A1
(es)
*
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
MX340558B
(es)
|
2010-08-24 |
2016-07-14 |
F Hoffmann-La Roche Ag * |
Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
BR112013020338A2
(pt)
|
2011-02-28 |
2016-10-18 |
Hoffmann La Roche |
proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US9151761B2
(en)
|
2011-06-29 |
2015-10-06 |
Amgen Inc. |
Predictive biomarker of survival in the treatment of renal cell carcinoma
|
EA033387B1
(ru)
|
2012-01-23 |
2019-10-31 |
Regeneron Pharma |
СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
EP2822594A4
(en)
|
2012-03-08 |
2016-02-17 |
Medimmune Llc |
METHODS OF TREATMENT WITH ANTI-ANGIOPOIETIN-2 ANTIBODIES
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
IN2014DN06904A
(fi)
|
2012-03-30 |
2015-05-15 |
Boehringer Ingelheim Int |
|
WO2014001324A1
(en)
|
2012-06-27 |
2014-01-03 |
Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
EP2867254B1
(en)
|
2012-06-27 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
AU2013288641B2
(en)
|
2012-07-13 |
2017-07-06 |
Roche Glycart Ag |
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
|
WO2014108854A1
(en)
|
2013-01-09 |
2014-07-17 |
Fusimab Ltd. |
Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
|
US10150800B2
(en)
|
2013-03-15 |
2018-12-11 |
Zyngenia, Inc. |
EGFR-binding modular recognition domains
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
BR112017005730B1
(pt)
|
2014-09-26 |
2023-12-12 |
Somalogic Operating Co., Inc |
Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
|
AU2015331602A1
(en)
|
2014-10-17 |
2017-04-27 |
Amgen Inc. |
Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
WO2016209972A1
(en)
|
2015-06-26 |
2016-12-29 |
Amgen Inc. |
Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
|
CN108366968B
(zh)
|
2015-12-16 |
2022-02-18 |
瑞泽恩制药公司 |
制造蛋白质微粒的组合物和方法
|
IL264962B1
(en)
|
2016-08-23 |
2024-05-01 |
Medimmune Ltd |
Antibodies against VEGF-A and against ANG2 and their uses
|
IL299270A
(en)
|
2017-01-30 |
2023-02-01 |
Regeneron Pharma |
Preparations and methods for reducing biological load in chromatography
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|